- New campaign will highlight Kate Walsh’s journey with dry
eye and how finding the right solution of Systane helped her
reconnect with what matters
- Partnership supports the launch of Systane Complete
Preservative-Free, the latest addition to Alcon’s #1
doctor-recommended over-the-counter dry eye brand
portfolio1
- Robust multimedia campaign drives consumers to find relief
from their dry eye symptoms with Systane Complete
Preservative-Free
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, today announced a partnership
with actress Kate Walsh, best known for her roles in Grey’s Anatomy
and Emily in Paris, to share her journey with dry eye around the
launch of its Systane® Complete Preservative-Free Lubricant Eye
Drops. As part of the new Make Every Look Count campaign, Walsh
will provide her personal testimonial about how her dry eye
symptoms have impacted important moments – on- and off-screen – and
how finding real relief with Systane has helped her reconnect to
what matters most.
“For years, I blamed my tired eyes on the bright lights on set,
too much screen time, the need for a new eye prescription and other
things. After I learned I had dry eye, I went on a journey to find
the right solution because the symptoms caused me to be distracted
during important moments – on- and off-set,” said Walsh. “Once I
found Systane, I knew I’d found an easy, on-the-go solution for my
dry eye symptoms that allowed me to take charge of my day. That’s
why I’m thrilled to partner with Alcon on the Make Every Look Count
campaign and help launch Systane Complete Preservative-Free
Lubricant Eye Drops. We hope this campaign will encourage others to
find what works for their dry eye symptoms, so they can reconnect
with loved ones and the experiences in life that matter most.”
Introduction of Systane Complete
Preservative-Free Lubricant Eye Drops Expands Alcon’s Portfolio of
Dry Eye Solutions
Systane Complete Preservative-Free Lubricant Eye Drops provides
eight hours of consistent dry eye symptom relief with just one
drop.2 The formula works to provide all-in-one dry eye symptom
relief by hydrating and supporting all layers of the tear
film.3,4,5 Its advanced, nano-droplet technology provides Alcon’s
best coverage, allowing for fast-acting hydration, tear evaporation
protection and long-lasting relief for a patient’s eyes.2,4 The
bottle also has a one-way valve to prevent contamination,
eliminating the need for preservatives in the eye drops.6
“Alcon is thrilled to partner with award-winning actress Kate
Walsh for the launch of one of our highly-anticipated dry eye
innovations. She’s a long-time Systane user, and we are excited to
introduce a product designed to closely meet her needs as someone
with dry, sensitive eyes,” said Sean Clark, General Manager, U.S.
Vision Care, Alcon. “The addition of Systane Complete
Preservative-Free to our portfolio means we can expand options and
deliver real, long-lasting relief to help people see brilliantly at
a time when dry eye symptoms are on the rise.”
Robust Multimedia Campaign Drives
Consumers to Find Real Relief for Dry Eye
A full-scale, multi-channel advertising campaign will run
throughout 2022, including organic and paid social content;
partnerships with social media influencers detailing their
experiences with dry eye; and a drive for consumers to learn more
about and try Systane Complete Preservative-Free Lubricant Eye
Drops. In celebration of Dry Eye Awareness Month in July, Alcon
will partner with an international charitable organization to help
communities in need of eye care.
As part of the campaign, Walsh will inspire people experiencing
dry eye symptoms to Make Every Look Count with Alcon’s newest
product innovation.
Systane Complete Preservative-Free Lubricant Eye Drops are
available in-store and online at all major retailers.
For more information, visit Systane.com.
Important Information for the Systane
Family of Products
Systane lubricant eye drops have been clinically proven to
reduce the symptoms of dry eye, providing fast, long-lasting relief
and comfort. Systane is the #1 recommended over-the-counter brand
in the dry eye category among Eye Care Professionals.1 Systane
Complete and Systane Complete Preservative-Free provide symptom
relief for people who suffer from evaporative dry eye, aqueous
tear-deficient dry eye or mixed dry eye. While Systane Ultra is
designed for patients with aqueous deficient dry eye, Systane
Balance lubricant eye drops are designed specifically for patients
with evaporative dry eye associated with meibomian gland
dysfunction. Systane Hydration Preservative-Free Lubricant Eye
Drops provide long-lasting hydration and restore moisture to dry
eyes with HydroBoost Technology.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 24,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
References
- Based on IQVIA ProVoice Survey of Eye Care Professionals 12
months ending December 31, 2021.
- Silverstein S. Yeu E, Tauber J. et al. Symptom Relief Following
a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion
in Patients with Dry Eye Disease: A Phase IV. Multicenter Trial.
Clin Ophthalmol.2020;14:3167-3177.m.
- Consumer Eye Drop Research, Global Path-To-Purchase; Alcon data
on file, 2017.
- Ketelson H, Rangarjan R. Pre-clinical evaluation of a nael
phospholipid nanoemulsion based lubricant eye drops. Poster
presented at ARVO 2017, Baltimore, MD.
- Rangarajan R, Ketelson H. Preclinical evaluation of a new
hydroxypropyl-guar phospholipid nanoemulsion-based artificial tear
formulation in models of corneal epithelium. J Ocul Pharmacol Ther.
2019;35(1):32-37.
- Nemera. Novelia Product Leaflet, 2018.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220406005980/en/
Investor Relations Allen
Trang + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Wes Warnock
+ 41 589 112 111 (Geneva) + 1 817 615 2501 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Apr 2023 to Apr 2024